Divis Laboratories' Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Divis Laboratories Ltd reported a 5.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.1%.
- Its expenses for the quarter were down by 5.6% QoQ and up 9.7% YoY.
- The net profit decreased 15.4% QoQ and decreased 1.0% YoY.
- The earnings per share (EPS) of Divis Laboratories Ltd stood at 21.98 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 2692.00 | 2860.00 | 2401.00 | -5.9% | 12.1% |
Total Expenses | 1838.00 | 1948.00 | 1675.00 | -5.6% | 9.7% |
Profit Before Tax | 780.00 | 912.00 | 726.00 | -14.5% | 7.4% |
Tax | 197.00 | 223.00 | 137.00 | -11.7% | 43.8% |
Profit After Tax | 583.00 | 689.00 | 589.00 | -15.4% | -1.0% |
Earnings Per Share | 21.98 | 25.97 | 22.20 | -15.4% | -1.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Divis Laboratories Ltd is a prominent player in the pharmaceutical industry. The company specializes in the manufacture of active pharmaceutical ingredients (APIs) and intermediates, serving a wide range of therapeutic areas. Known for its strong emphasis on research and development, Divis Laboratories has established itself as a reliable supplier to pharmaceutical companies worldwide. The company operates state-of-the-art manufacturing facilities and has a strong global footprint. While specific recent developments are not detailed here, Divis Laboratories is recognized for its consistent focus on innovation and quality in pharmaceutical manufacturing.
Revenue
In Q3FY26, Divis Laboratories reported a total income of ₹2,692 crore, which represents a decrease of 5.9% quarter-over-quarter (QoQ) from ₹2,860 crore in Q2FY26. However, there was a year-over-year (YoY) increase of 12.1% compared to ₹2,401 crore in Q3FY25. This indicates a positive annual revenue growth despite a quarterly decline. The fluctuation in revenue could be attributed to various factors, including market dynamics and operational adjustments. The revenue trends are indicative of the company's performance in the pharmaceutical sector and reflect its ability to adapt to changing industry conditions.
Profitability
The company's profit before tax for Q3FY26 was ₹780 crore, showing a decline of 14.5% QoQ from ₹912 crore in Q2FY26. On a YoY basis, there was a 7.4% increase from ₹726 crore in Q3FY25. The tax expense for the quarter stood at ₹197 crore, marking an 11.7% decrease QoQ from ₹223 crore but a significant 43.8% increase YoY from ₹137 crore. Consequently, the profit after tax was ₹583 crore for Q3FY26, down by 15.4% QoQ from ₹689 crore and slightly lower by 1.0% YoY from ₹589 crore. Earnings per share mirrored the profit after tax trend, with a value of ₹21.98 in Q3FY26, reflecting the same percentage changes as the profit after tax. These figures provide insight into the company's profitability trends over the past quarters.
Operating Metrics
Total expenses for Q3FY26 were reported at ₹1,838 crore, which is a decrease of 5.6% QoQ from ₹1,948 crore in Q2FY26, and an increase of 9.7% YoY from ₹1,675 crore in Q3FY25. This indicates a reduction in operating costs on a quarterly basis but an increase annually. The company's ability to manage expenses effectively is crucial for maintaining profitability and operational efficiency. The financial metrics, including total income, expenses, and profitability, are indicative of Divis Laboratories' operational performance and financial health in the pharmaceutical industry.